Home Cart Sign in  
Chemical Structure| 35846-53-8 Chemical Structure| 35846-53-8

Structure of Maytansine
CAS No.: 35846-53-8

Chemical Structure| 35846-53-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Maitansine is a cytotoxic agent. It inhibits the assembly of microtubules by binding to tubulin at the rhizoxin binding site.

Synonyms: NSC 153858; Maitansine; Mertansine.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Maytansine

CAS No. :35846-53-8
Formula : C34H46ClN3O10
M.W : 692.20
SMILES Code : C[C@@]12[C@@H](O2)[C@H](C)[C@]([H])(C[C@](N3)(O)[C@]([H])(OC)/C=C/C=C(CC4=CC(N(C(C[C@@]1(OC([C@@H](N(C(C)=O)C)C)=O)[H])=O)C)=C(Cl)C(OC)=C4)\C)OC3=O
Synonyms :
NSC 153858; Maitansine; Mertansine.
MDL No. :MFCD28127038

Safety of Maytansine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Maytansine

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 0.01237 ng/mL (IC50) 48 hours To evaluate the cytotoxicity of DM1-loaded ZNPs on A549 cells, results showed that DM1-loaded ZNPs exhibited stronger anti-proliferation capacity compared to free DM1. PMC6968508

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02318901 - Terminated(PI no longer at sig... More >>ht. Results not collected) Less << - -
NCT02318901 Advanced Cancer ... More >> Breast Cancer Gastric Cancer Esophageal Cancer Colorectal Cancer Less << Phase 1 Phase 2 Terminated(PI no longer at sig... More >>ht. Results not collected) Less << - United States, Arizona ... More >> Western Regional Medical Center/Cancer Treatment Center of America Goodyear, Arizona, United States, 85338 Less <<
NCT02465060 Advanced Malignant Solid Neopl... More >>asm Bladder Carcinoma Breast Carcinoma Cervical Carcinoma Colon Carcinoma Colorectal Carcinoma Endometrial Carcinoma Esophageal Carcinoma Gastric Carcinoma Glioma Head and Neck Carcinoma Kidney Carcinoma Liver and Intrahepatic Bile Duct Carcinoma Lung Carcinoma Lymphoma Malignant Uterine Neoplasm Melanoma Ovarian Carcinoma Pancreatic Carcinoma Plasma Cell Myeloma Prostate Carcinoma Rectal Carcinoma Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Cervical Carcinoma Recurrent Colon Carcinoma Recurrent Colorectal Carcinoma Recurrent Esophageal Carcinoma Recurrent Gastric Carcinoma Recurrent Glioma Recurrent Head and Neck Carcinoma Recurrent Liver Carcinoma Recurrent Lung Carcinoma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Ovarian Carcinoma Recurrent Pancreatic Carcinoma Recurrent Plasma Cell Myeloma Recurrent Prostate Carcinoma Recurrent Rectal Carcinoma Recurrent Skin Carcinoma Recurrent Thyroid Gland Carcinoma Recurrent Uterine Corpus Carcinoma Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Plasma Cell Myeloma Skin Carcinoma Thyroid Gland Carcinoma Uterine Corpus Cancer Less << Phase 2 Recruiting - -
NCT02605915 HER2-Positive Metastatic Breas... More >>t Cancer HER2-Negative Metastatic Breast Cancer Locally Advanced or Early Breast Cancer Less << Phase 1 Active, not recruiting October 31, 2019 United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294-3300 United States, Arkansas University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute Little Rock, Arkansas, United States, 72205 United States, Illinois Joliet oncology hematology associates Joliet, Illinois, United States, 60435 United States, Indiana Horizon Oncology Research, Inc. Lafayette, Indiana, United States, 47905 United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21287 United States, Michigan Karmanos Cancer Center; Department of Oncology Detroit, Michigan, United States, 48201 United States, Missouri HCA Midwest Division Kansas City, Missouri, United States, 64132 United States, New York Montefiore Medical Center, Advanced Women's Health Center, Clinical Trials and Research Unit; Depart Bronx, New York, United States, 10461 United States, North Carolina Levine Cancer Institute Charlotte, North Carolina, United States, 28204 Duke Cancer Center Durham, North Carolina, United States, 27710 United States, Ohio Oncology Hematology Care Inc Cincinnati, Ohio, United States, 45242 United States, Pennsylvania St. Luke's University Health Network Bethlehem, Pennsylvania, United States, 18015 Kimmel Cancer Center Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Magee Womens Hospital Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee Tennessee Oncology - Chattanooga; Tennessee Oncology - East Third Street Chattanooga, Tennessee, United States, 37404 West Clinic Germantown, Tennessee, United States, 38138 Tennessee Oncology Nashville, Tennessee, United States, 37203 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Cancer Therapy and Research Center CTRC at UTHSCSA San Antonio, Texas, United States, 78229 United States, Wisconsin Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Less <<
NCT02606305 Epithelial Ovarian Cancer ... More >> Primary Peritoneal Cancer Fallopian Tube Cancer Less << Phase 1 Phase 2 Recruiting July 2021 United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, Ohio The Ohio State University Recruiting Hilliard, Ohio, United States, 43026 United States, Oklahoma Peggy and Charles Stephenson Oklahoma Cancer Center Recruiting Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Fox Chase Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19111 Belgium Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut Recruiting Leuven, Belgium, 3000 Canada Hamilton Health Sciences Center Recruiting Hamilton, Canada Centre Hospitalier de l'universite de Montreal (CHUM) Recruiting Montreal, Canada McGill University Recruiting Montreal, Canada Spain MD Anderson Suspended Madrid, Spain, 28033 Less <<
NCT00781612 Neoplasm Metastasis Phase 2 Recruiting September 21, 2022 -
NCT01120184 Breast Cancer Phase 3 Completed - -
NCT02073487 Breast Cancer Phase 2 Active, not recruiting June 2019 United States, Texas ... More >> Houston Methodist Hospital Houston, Texas, United States, 77030 Houston Methodist Hospital Willowbrook Houston, Texas, United States, 77070 Houston Methodist Hospital Sugar Land Sugar Land, Texas, United States, 77479 Less <<
NCT03364348 HER2 Positive Breast Carcinoma... More >> Recurrent Breast Carcinoma Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Less << Phase 1 Recruiting October 2021 United States, California ... More >> Stanford University, School of Medicine Recruiting Palo Alto, California, United States, 94304 Contact: Oshra Sedan    650-723-0628    osedan@stanford.edu    Principal Investigator: George W. Sledge, MD Less <<
NCT03587311 Fallopian Tube Endometrioid Ad... More >>enocarcinoma High Grade Fallopian Tube Serous Adenocarcinoma High Grade Ovarian Serous Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Platinum-Resistant Ovarian Carcinoma Primary Peritoneal High Grade Serous Adenocarcinoma Refractory Fallopian Tube Carcinoma Refractory Ovarian Carcinoma Refractory Primary Peritoneal Carcinoma Less << Phase 2 Recruiting April 30, 2019 United States, Ohio ... More >> Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact    800-293-5066    Jamesline@osumc.edu    Principal Investigator: David M. O'Malley          Canada, Ontario University Health Network-Princess Margaret Hospital Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Site Public Contact    416-946-4501    clinical.trials@uhn.on.ca    Principal Investigator: Stephanie Lheureux Less <<
NCT02631876 Epithelial Ovarian Cancer ... More >> Primary Peritoneal Carcinoma Fallopian Tube Cancer Ovarian Cancer Less << Phase 3 Active, not recruiting February 2019 -
NCT01120184 - Completed - -
NCT02314481 Non-small Cell Lung Cancer Phase 2 Recruiting January 2023 United Kingdom ... More >> Univeristy College London Hospital Recruiting London, United Kingdom Contact: Amy Smith Less <<
NCT02226276 Bone Metastases ... More >> HER2-positive Breast Cancer Liver Metastases Lung Metastases Recurrent Breast Cancer Soft Tissue Metastases Stage IV Breast Cancer Less << Not Applicable Active, not recruiting February 2019 United States, California ... More >> City of Hope Medical Center Duarte, California, United States, 91010 Less <<
NCT03529110 Breast Cancer Phase 3 Recruiting February 2022 United States, California ... More >> Cancer Research Collaboration Recruiting Santa Ana, California, United States, 92705 Contact: Principal Investigator    562-981-6101    WadeSmith@veritymed.org    United States, District of Columbia Washington Cancer Institute Recruiting Washington, District of Columbia, United States, 20010 Contact: Site Coordinator    202-877-9386    mhri.oncology@medstar.net    United States, New York North Shore Hematology Oncology Associates, PC Recruiting East Setauket, New York, United States, 11733 Contact: Site Coordinator    631-675-5143    dmarx@nycancer.com    United States, Tennessee Tennessee Oncology- St Thomas Location Recruiting Nashville, Tennessee, United States, 37205 Contact: Site Coordinator    615-524-4016    cann.studyactivation@sarahcannon.com    United States, Washington MultiCare Health System Institute for Research and Innovation Recruiting Auburn, Washington, United States, 98001 Contact: Site Coordinator    253-209-8972    srebar@multicare.org    Japan Hiroshima City Hiroshima Citizens Hospital Recruiting Hiroshima, Hiroshima-Ken, Japan, 730-8518 Contact: See Central Contact          Showa University Hospital Recruiting Shinagawa-Ku, Tokyo-To, Japan, 142-8666 Contact: See Central Contact          Aichi Cancer Center Hospital Recruiting Aichi, Japan, 464-8681 Contact: See Central Contact          NHO Hokkaido Cancer Center Recruiting Hokkaido, Japan, 003-0804 Contact: See Central Contact          Kanagawa Cancer Center Recruiting Kanagawa, Japan, 241-8515 Contact: See Central Contact          Niigata Cancer Center Recruiting Niigata, Japan, 951-8566 Contact: See Central Contact          NHO Osaka National Hospital Recruiting Osaka, Japan, 540-0006 Contact: See Central Contact          Osaka International Cancer Institute Recruiting Osaka, Japan, 541-8567 Contact: See Central Contact          Satiama Cancer Center Recruiting Saitama, Japan, 362-0806 Contact: See Central Contact          The Cancer Institute Hospital of JFCR Recruiting Tokyo, Japan, 135-8550 Contact: See Central Contact Less <<
NCT00951665 Metastatic Breast Cancer Phase 1 Phase 2 Completed - United States, California ... More >> Stanford, California, United States, 94305-5456 United States, Colorado Aurora, Colorado, United States, 80045 United States, Massachusetts Boston, Massachusetts, United States, 02115 United States, Michigan Detroit, Michigan, United States, 48201 United States, New York New York, New York, United States, 10065 Less <<
NCT00951665 - Completed - -
NCT02390427 Metastatic Breast Cancer ... More >> Recurrent Breast Cancer Less << Phase 1 Recruiting October 2020 United States, Massachusetts ... More >> Massacusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Dejan Juric, MD    617-724-6500    djuric@partners.org    Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Ian Krop, MD, PhD    617-632-6973    IKROP@PARTNERS.ORG    United States, Tennessee Sarah Cannon Research Institute Recruiting Nashville, Tennessee, United States, 37203 Contact: Erika Hamilton, MD       ehamilton@tnonc.com Less <<
NCT00829166 Breast Cancer Phase 3 Completed - -
NCT01237678 Small Cell Lung Cancer Phase 1 Phase 2 Terminated(Study was stopped e... More >>arly due to lack of efficacy signal and safety concerns) Less << - -
NCT02073916 Metastatic Breast Cancer Phase 1 Active, not recruiting December 2018 United States, Texas ... More >> Houston Methodist Hospital Houston, Texas, United States, 77030 Less <<
NCT03709082 HER2-positive Breast Cancer ... More >> Breast Cancer Metastatic Less << Phase 1 Phase 2 Recruiting October 15, 2025 United States, Kansas ... More >> The University of Kansas Cancer Center, West Clinic Recruiting Kansas City, Kansas, United States, 66112 Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu    The University of Kansas Cancer Center, Westwood Campus Recruiting Kansas City, Kansas, United States, 66205 Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu    The University of Kansas Cancer Center, Overland Park Clinic Recruiting Overland Park, Kansas, United States, 66210 Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu    United States, Missouri The University of Kansas Cancer Center, North Clinic Recruiting Kansas City, Missouri, United States, 64154 Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu    The University of Kansas Cancer Center, Lee's Summit Clinic Recruiting Lee's Summit, Missouri, United States, 64064 Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu Less <<
NCT01966471 Breast Cancer Phase 3 Active, not recruiting January 31, 2024 -
NCT01237678 - Terminated(Study was stopped e... More >>arly due to lack of efficacy signal and safety concerns) Less << - -
NCT00875979 Metastatic Breast Cancer Phase 1 Phase 2 Completed - United States, Florida ... More >> Boca Raton, Florida, United States, 33428 Deerfield Beach, Florida, United States, 33442 United States, Illinois Maywood, Illinois, United States, 60153 United States, Indiana Indianapolis, Indiana, United States, 46202 United States, Kansas Wichita, Kansas, United States, 67214 United States, Maryland Rockville, Maryland, United States, 20850-3348 United States, North Carolina Chapel Hill, North Carolina, United States, 27514 United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Nashville, Tennessee, United States, 37203 Belgium Bruxelles, Belgium, 1000 Canada, British Columbia Vancouver, British Columbia, Canada, V5Z 1H5 Canada, Quebec Montreal, Quebec, Canada, H3A 1A1 France Paris, France, 75248 Villejuif, France, 94805 Germany Köln, Germany, 50924 Italy Aviano, Italy, 33081 Milano, Italy, 20133 Spain Barcelona, Spain, 08035 Valencia, Spain, 46010 Less <<
NCT02658084 Breast Cancer ... More >> Metastatic Breast Cancer Less << Phase 1 Phase 2 Terminated(Terminated due to l... More >>ow accrual and toxicity concerns.) Less << - United States, Florida ... More >> University of Miami Miami, Florida, United States, 33136 Less <<
NCT00829166 - Completed - -
NCT02414646 Estrogen Receptor Status ... More >> HER2 Positive Breast Carcinoma Progesterone Receptor Status Stage I Breast Cancer AJCC v7 Stage IA Breast Cancer AJCC v7 Stage IB Breast Cancer AJCC v7 Stage II Breast Cancer AJCC v6 and v7 Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Less << Phase 2 Active, not recruiting January 31, 2022 United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 United States, Illinois Illinois CancerCare-Peoria Peoria, Illinois, United States, 61615 United States, Kansas Cancer Center of Kansas - Wichita Wichita, Kansas, United States, 67214 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Michigan Cancer Research Consortium NCORP Ann Arbor, Michigan, United States, 48106 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New York State University of New York Upstate Medical University Syracuse, New York, United States, 13210 United States, North Carolina UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 High Point Regional Hospital High Point, North Carolina, United States, 27262 FirstHealth of the Carolinas-Moore Regional Hospital Pinehurst, North Carolina, United States, 28374 United States, Ohio Columbus NCI Community Oncology Research Program Columbus, Ohio, United States, 43215 Toledo Clinic Cancer Centers-Toledo Toledo, Ohio, United States, 43623 United States, Virginia Inova Fairfax Hospital Falls Church, Virginia, United States, 22042 Less <<
NCT01853748 Breast Cancer Phase 2 Active, not recruiting December 2021 -
NCT02947152 Epithelial Ovarian Cancer ... More >> Renal Cell Carcinoma Less << Phase 1 Terminated - United States, Texas ... More >> Novartis Investigative Site Houston, Texas, United States, 77030 Australia, Victoria Novartis Investigative Site Melbourne, Victoria, Australia, 3000 Belgium Novartis Investigative Site Leuven, Belgium, 3000 Japan Novartis Investigative Site Nagoya, Aichi, Japan, 466 8560 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Switzerland Novartis Investigative Site Locarno, Switzerland, 6600 Less <<
NCT00875979 - Completed - -
NCT00679341 Breast Cancer Phase 2 Completed - -
NCT00833963 - Recruiting January 31, 2025 United States, North Carolina ... More >> Kendle International, Inc Recruiting Wilmington, North Carolina, United States, 28405 Less <<
NCT00679341 - Completed - -
NCT00943670 Metastatic Breast Cancer Phase 2 Completed - -
NCT01494662 Breast Cancer Phase 2 Recruiting December 2023 United States, California ... More >> University of California, San Francisco Medical Center Active, not recruiting San Francisco, California, United States, 94115 United States, District of Columbia MedStar Georgetown Univeristy Hospital Active, not recruiting Washington, District of Columbia, United States, 20007 United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Active, not recruiting Baltimore, Maryland, United States, 21231 United States, Massachusetts Beth Israel Deaconess Medical Center Active, not recruiting Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Rachel Freedman, MD          Principal Investigator: Rachel Freedman, MD, MPH          Massachusetts General Hosptial Recruiting Boston, Massachusetts, United States, 02215 Contact: Beverly Moy, MD          Principal Investigator: Beverly Moy, MD          United States, Michigan University of Michigan Comprehensive Cancer Center Active, not recruiting Ann Arbor, Michigan, United States, 48109 United States, North Carolina University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center Active, not recruiting Chapel Hill, North Carolina, United States, 27599 Duke University Medical Center Active, not recruiting Durham, North Carolina, United States, 27710 United States, Pennsylvania UPMC Cancer Centers - Magee-Womens Hospital of UPMC Active, not recruiting Pittsburgh, Pennsylvania, United States, 15213 United States, Texas Baylor College of Medicine Lester and Sue Smith Breast Center Active, not recruiting Houston, Texas, United States, 77030 MD Anderson Cancer Center Active, not recruiting Houston, Texas, United States, 77030 Less <<
NCT01904903 HER2 Positive Breast Cancer ... More >> Left Ventricular Function Systolic Dysfunction Less << Phase 2 Unknown August 2018 United States, District of Col... More >>umbia Washington Cancer Institute at MedStar Washington Hospital Center Recruiting Washington, District of Columbia, United States, 20010 Contact: Ronla Prince, MPA          Contact: Filipa Lynce, MD          Principal Investigator: Sandra M Swain, MD, FACP          Sub-Investigator: Ana Barac, MD, PhD          Sub-Investigator: Filipa Lynce, MD          MedStar Georgetown University Hospital Recruiting Washington, District of Columbia, United States, 20057 Contact: Julie Castle    202-687-2209    bickmorj@georgetown.edu    Contact: Antonella Novielli    2024443923    noviella@georgetown.edu    Principal Investigator: Filipa Lynce, MD Less <<
NCT02038010 HER2-positive Breast Cancer ... More >> Recurrent Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Less << Phase 1 Active, not recruiting March 2020 United States, Illinois ... More >> Northwestern University Chicago, Illinois, United States, 60611 Less <<
NCT02144012 Metastatic Breast Cancer Phase 3 Terminated - Korea, Republic of ... More >> Daegu, Korea, Republic of, 702-210 Gyeonggi-do, Korea, Republic of, 410-769 Seoul, Korea, Republic of, 05505 Malaysia Sabah, Malaysia, 88996 Taiwan Taipei, Taiwan, 00112 Taipei, Taiwan, 100 Taoyuan, Taiwan, 333 Thailand Bangkok, Thailand, 10330 Less <<
NCT02658734 HER2 Positive Breast Cancer, M... More >>etastatic Breast Cancer, Locally Advanced Breast Cancer Less << Phase 4 Recruiting December 2, 2020 India ... More >> Indraprastha Apollo Hospitals Recruiting New Delhi, Delhi, India, 110076 Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology Recruiting New Delhi, Delhi, India, 110085 Max Super Speciality Hospital; Medical Oncology Active, not recruiting North WEST Delhi, Delhi, India, 110088 Apollo Hospitals International Limited Recruiting Gandhinagar, Gujarat, India, 382428 Manipal Hospital; Department of Oncology Recruiting Bangalore, Karnataka, India, 560017 Tata Memorial Hospital; Dept of Medical Oncology Active, not recruiting Mumbai, Maharashtra, India, 400012 Jehangir Hospital Active, not recruiting Pune, Maharashtra, India, 411001 Christian Medical College & Hospital; Medicine Recruiting Vellore, Tamil NADU, India, 632004 Healthcare Global Enterprises Limited Recruiting Bangalore, India, 560027 Vikram Hospital Bengaluru Private Limited Withdrawn Bengaluru, India, 560 052 Artemis Health Institute Active, not recruiting Gurgaon, India, 122001 Fortis Memorial Research Institute; Department of Medical Oncology & Haematology Recruiting Gurgaon, India, 122002 Sir Gangaram Hospital; Medical Oncology Completed New Delhi, India, 110 060 Dr. B L Kapur Memorial Hospital; BLK Cancer Centre Withdrawn New Delhi, India, 110005 Max Super Speciality Hospital Recruiting New Delhi, India, 110017 Less <<
NCT02144012 - Terminated - -
NCT01745965 Breast Cancer Phase 2 Active, not recruiting October 2020 Germany ... More >> Breast Center of the University of Munich (LMU) Munich, Germany Ev. Krankenhaus Bethesda Brustzentrum Niederrhien Mönchengladbach, Germany Less <<
NCT01816035 HER2/Neu Positive ... More >> Recurrent Breast Carcinoma Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Less << Phase 1 Completed - United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 Less <<
NCT03025711 - Recruiting December 31, 2018 Spain ... More >> Puerta de Hierro University Hospital Recruiting Madrid, Spain, 28222 Contact: Belen Ruiz-Antoran    34911917479    mariabelen.ruiz@salud.madrid.org    Principal Investigator: Belen Ruiz-Antorán Less <<
NCT03032107 Breast Cancer Phase 1 Recruiting July 1, 2024 United States, Massachusetts ... More >> Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Gerburg Wulf, MD PhD    617-667-1910       Principal Investigator: Gerburg Wulf, MD PhD          Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Sara Tolaney, MD MPH    617-632-3779    stolaney@partners.org    Principal Investigator: Sara Tolaney, MD MPH Less <<
NCT02639091 Medical Oncology Phase 1 Active, not recruiting June 28, 2019 United States, Illinois ... More >> Chicago, Illinois, United States, 60637 United States, Maryland Bethesda, Maryland, United States, 20892 United States, Michigan Detroit, Michigan, United States, 48202 United States, South Carolina Charleston, South Carolina, United States, 29425 Italy Milano, Lombardia, Italy, 20089 Milano, Lombardia, Italy, 20133 Less <<
NCT00943670 - Completed - -
NCT03418558 Metastatic Colorectal Cancer Phase 2 Recruiting June 2019 Italy ... More >> Fondazione del Piemonte per l'Oncologia Completed Candiolo, Italy, 10060 Grande Ospedale Metropolitano Niguarda Recruiting Milano, Italy Contact: Salvatore Siena, MD       salvatore.siena@ospedaleniguarda.it    IOV - Istituto Oncologico Veneto Completed Padova, Italy Less <<
NCT03045393 Breast Cancer Triple Negative Phase 1 Withdrawn(Inadequate enrollmen... More >>t) Less << - United States, North Carolina ... More >> Duke University Medical Center Durham, North Carolina, United States, 27710 Less <<
NCT02610140 Mesothelioma Phase 2 Active, not recruiting July 29, 2019 -
NCT02824042 Medical Oncology Phase 1 Active, not recruiting June 28, 2019 United States, California ... More >> UCLA-Santa Monica Medical Center Santa Monica, California, United States, 90404 United States, Michigan Henry Ford Health System Detroit, Michigan, United States, 48202 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio University Hospitals Cleveland Medical Center Cleveland, Ohio, United States, 44106-2602 United States, Texas Mary Crowley Medical Research Center Dallas, Texas, United States, 75230 Australia, New South Wales Blacktown Cancer & Haematology Centre Blacktown, New South Wales, Australia, 2148 Australia, Victoria Epworth HealthCare Richmond, Victoria, Australia, 3122 Belgium CU Saint-Luc/UZ St-Luc Bruxelles - Brussel, Belgium, 1200 UZ Gent Gent, Belgium, 9000 France Hôpital Henri Mondor Creteil, France, 94010 Centre Georges Francois Leclerc Dijon Dijon, France, 21000 Hôpital de la Timone - Marseille Marseille, France, 13005 Netherlands Nederlands Kanker Instituut Amsterdam, Netherlands, 1066 CX Academisch Ziekenhuis Vrije Universiteit Amsterdam, Netherlands, 1081 HV Universitair Medisch Centrum St. Radboud Nijmegen, Netherlands, 6525 GA Spain Ciutat Sanitària i Universitaria de la Vall d'Hebron Barcelona, Spain, 08035 Fundacion Jimenez Diaz (Clinica de la Concepcion) Madrid, Spain, 28040 Hospital Virgen de la Victoria Málaga, Spain, 29010 Less <<
NCT03102320 Neoplasms Phase 1 Recruiting July 28, 2021 -
NCT03225937 Metastatic Colorectal Cancer Phase 2 Active, not recruiting June 2019 Italy ... More >> Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo, Please Select, Italy, 10060 AOU Policlinico S. Orsola Malpighi Bologna, Italy Grande Ospedale Metropolitano Niguarda Milano, Italy, 20162 Seconda Università di Napoli Napoli, Italy Istituto Oncologico Veneto - IRCCS Padova, Italy Campus Biomedico Roma, Italy AOU Città della Salute e della Scienza di Torino Torino, Italy Less <<
NCT03455556 Mesothelin Positive ... More >> Stage III Non-Small Cell Lung Cancer AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Non-Small Cell Lung Cancer AJCC v7 Stage IV Non-Small Cell Lung Cancer AJCC v7 Less << Phase 1 Phase 2 Recruiting October 23, 2020 United States, Arizona ... More >> Mayo Clinic Hospital Recruiting Phoenix, Arizona, United States, 85054 Contact: Clinicial Trials Referral Office    855-776-0015       Principal Investigator: Helen J. Ross          United States, Florida Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Clinical Trials Referral Office    855-776-0015       Principal Investigator: Yanyan Lou          United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office    855-776-0015       Principal Investigator: Alex A. Adjei Less <<
NCT02751918 Ovarian Neoplasms Phase 1 Recruiting September 25, 2020 United States, California ... More >> University of California, Los Angeles Not yet recruiting Los Angeles, California, United States, 90095 United States, Colorado Rocky Mountain Cancer Centers Recruiting Aurora, Colorado, United States, 80012 United States, Connecticut Yale University School of Medicine Recruiting New Haven, Connecticut, United States, 06520-8064 United States, Ohio University of Cincinnati Not yet recruiting Cincinnati, Ohio, United States, 45267 United States, Oklahoma Oklahoma University Health Science Center Recruiting Oklahoma City, Oklahoma, United States, 73104 United States, Oregon Oncology Associates of Oregon Not yet recruiting Eugene, Oregon, United States, 97401 Belgium UZ Leuven Gasthuisberg Recruiting Leuven, Belgium, 3000 France Institut Gustave Roussy Not yet recruiting Villejuif Cedex, France, 94805 Japan Aichi Cancer Center Hospital Not yet recruiting Nagoya, Aichi, Japan, 464-8681 Nippon Medical School Musashikosugi Hospital Not yet recruiting Kawasaki, Kanagawa, Japan, 211-8533 Saitama Medical University International Medical Center Not yet recruiting Hidaka, Saitama, Japan, 350-1298 National Cancer Center Hospital Not yet recruiting Chuo-ku, Tokyo, Japan, 104-0045 Moldova, Republic of The Institute of Oncology Recruiting Chisinau, Moldova, Republic of, 2025 Spain Ciutat Sanitària i Universitaria de la Vall d'Hebron Recruiting Barcelona, Spain, 08035 Clinica Universidad de Navarra CUN en Madrid Recruiting Madrid, Spain, 28027 Clínica Universidad de Navarra CUN Recruiting Pamplona, Spain, 31008 Instituto Valenciano de Oncología Recruiting Valencia, Spain, 46009 Less <<
NCT02131064 Breast Neoplasms Phase 3 Completed - -
NCT02924883 Metastatic Breast Cancer Phase 2 Active, not recruiting November 24, 2020 -
NCT03084939 Breast Cancer Phase 3 Active, not recruiting October 5, 2019 China ... More >> Beijing Hospital Beijing City, China, 100006 The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA) Beijing, China, 100071 Beijing Cancer Hospital Beijing, China, 100142 Jilin Cancer Hospital Changchun, China, 130012 the First Hospital of Jilin University Changchun, China, 130021 Changzhou First People's Hospital Changzhou, China, 213003 West China Hospital, Sichuan University Chengdu, China, 610041 Fujian Medical University Union Hospital Fujian, China, 350001 Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department Hangzhou City, China, 310022 The Second Affiliated Hospital of Zhejiang University College Hangzhou, China, 310009 Harbin Medical University Cancer Hospital Harbin, China, 150081 Jiangsu Cancer Hospital Nanjing, China, 210009 Jiangsu Province Hospital Nanjing, China, 210036 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China, 200025 Fudan University Shanghai Cancer Center Shanghai, China, 200032 Liaoning cancer Hospital & Institute Shenyang, China, 110042 Tianjin Cancer Hospital Tianjin, China, 300060 First Affiliated Hospital of Medical College of Xi'an Jiaotong University Xi'an, China, 710061 Less <<
NCT01641939 Gastric Cancer Phase 2 Phase 3 Terminated - -
NCT02131064 - Completed - -
NCT00509769 Metastatic Breast Cancer Phase 2 Completed - -
NCT00679211 Metastatic Breast Cancer Phase 2 Completed - -
NCT00679211 - Completed - -
NCT00932373 Metastatic Breast Cancer Phase 1 Completed - -
NCT00928330 Metastatic Breast Cancer Phase 1 Completed - United States, Indiana ... More >> Indianapolis, Indiana, United States, 46202 United States, Maryland Baltimore, Maryland, United States, 21231 United States, Massachusetts Boston, Massachusetts, United States, 02115 Less <<
NCT01641939 - Terminated - -
NCT00932373 - Completed - -
NCT01196052 - Completed - -
NCT01419197 Breast Cancer Phase 3 Completed - -
NCT01513083 Breast Cancer Phase 1 Completed - United States, Florida ... More >> Fort Myers, Florida, United States, 33905 United States, Michigan Detroit, Michigan, United States, 48201 United States, Oregon Portland, Oregon, United States, 97239 United States, Tennessee Nashville, Tennessee, United States, 37203 Canada, Ontario Ottawa, Ontario, Canada, K1H8L6 Toronto, Ontario, Canada, M5G 2M9 France Marseille, France, 13273 Paris, France, 75231 Toulouse, France, 31059 Italy Catanzaro, Calabria, Italy, 88100 Udine, Friuli-Venezia Giulia, Italy, 33100 Spain Barcelona, Spain, 08003 Madrid, Spain, 28007 Less <<
NCT00509769 - Completed - -
NCT01419197 - Completed - -
NCT01772472 Breast Cancer Phase 3 Active, not recruiting April 4, 2023 -
NCT01975142 Metastatic Breast Cancer Consi... More >>dered HER2 Negative on Primary Tumor Less << Phase 2 Unknown November 2017 France ... More >> Clinique Victor Hugo Le Mans, France, 72000 Institut de Cancérologie HARTMANN Levallois-perret, France, 92309 Centre Oscar Lambret Lille, France, 59020 Chu de Limoges Limoges, France, 87042 Centre Val d'Aurelle - P. Lamarque Montpellier, France, 34298 Institut Curie Paris, France, 75005 Chu Saint-Louis Paris, France, 75475 Institut Curie - Hôpital René HUGENIN Saint-cloud, France, SAINT-CLOUD Centre Catherine de Sienne Vandoeuvre Les Nancy, France, 54519 Institut de Cancérologie de Lorraine Vandoeuvre Les Nancy, France, 54519 Less <<
NCT01120561 - - - United States, California ... More >> Investigational Site Highland, California, United States, 92346 Investigational Site Stockton, California, United States, 95204 United States, Colorado Investigational Site Denver, Colorado, United States, 80220 United States, Florida Investigational Site Plantation, Florida, United States, 33324 United States, Indiana Investigational Site Lafayette, Indiana, United States, 47905 United States, Iowa Investigational Site Cedar Rapids, Iowa, United States, 52403 United States, Maine Investigational Site Scarborough, Maine, United States, 04074 United States, Maryland Investigational Site Baltimore, Maryland, United States, 21231 United States, Michigan Investigational Site Detroit, Michigan, United States, 48201 United States, Missouri Investigational Site Clarkson Valley, Missouri, United States, 63011 United States, New Mexico Investigational Site Farmington, New Mexico, United States, 87401 United States, North Carolina Investigational Site Charlotte, North Carolina, United States, 28203 United States, South Carolina Investigational Site Charleston, South Carolina, United States, 29403 United States, Virginia Investigational Site Fairfax, Virginia, United States, 22031 United States, Washington Investigational Site Seattle, Washington, United States, 98109 Less <<
NCT01196052 Breast Cancer Phase 2 Completed - -
NCT01976169 Advanced Breast Cancer Phase 1 Recruiting December 2020 United States, Texas ... More >> UT Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390 Contact: Barbara Haley, MD    214-648-4180    barbara.haley@utsouthwestern.edu    Contact: Gregg Wright    214-648-7097    James.Wright@UTSouthwestern.edu    Sub-Investigator: Dawn Klemow, MD          Sub-Investigator: Erik Knudsen, MD          Sub-Investigator: Navid Sadeghi, MD          Sub-Investigator: Lori Watumull, MD          Principal Investigator: Barbara Haley, MD Less <<
NCT02236000 Breast Cancer Phase 1 Phase 2 Recruiting July 2019 United States, Florida ... More >> Cleveland Clinic Weston Recruiting Weston, Florida, United States, 33331 United States, Illinois Cancer Care Specialists of Central Illinois Recruiting Decatur, Illinois, United States, 62526 Crossroads Cancer Center Recruiting Effingham, Illinois, United States, 62401 Cancer Care Specialists of Central Illinois-Swansea Recruiting Swansea, Illinois, United States, 62226 United States, Ohio Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Diana Gosik, RN, BS    800-270-3165       United States, Oklahoma Stephenson Cancer Center at the University of Oklahoma Health Services Center Recruiting Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania UPMC- Hillman Cancer Center-Monroeville Recruiting Monroeville, Pennsylvania, United States, 15146 Alleheny General Hospital Recruiting Pittsburgh, Pennsylvania, United States, 15212 Hillman Cancer Center Recruiting Pittsburgh, Pennsylvania, United States, 15213 Magee Womens Hospital of UPMC Recruiting Pittsburgh, Pennsylvania, United States, 15213 Contact: Diana Gosik, RN, BS    800-270-3165       University of Pittsburgh Recruiting Pittsburgh, Pennsylvania, United States, 15213 UPMC- St. Margaret Recruiting Pittsburgh, Pennsylvania, United States, 15215 United States, Rhode Island Women & Infants Hospital of Rhode Island Recruiting Providence, Rhode Island, United States, 02905 Contact: Diana Gosik, RN, BS    800-270-3165       United States, West Virginia West Virginia University Recruiting Morgantown, West Virginia, United States, 26501 Contact: Diana Gosik, RN, BS    800-270-3165 Less <<
NCT01983501 HER2 Positive Breast Cancers Phase 1 Active, not recruiting July 2019 United States, Alabama ... More >> University of Alabama Birmingham, Alabama, United States, 35294 United States, Colorado University of Colorado Cancer Center Aurora, Colorado, United States, 80045 United States, Kansas University of Kansas Kansas City, Kansas, United States, 66160 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Oregon Providence Cancer Center Portland, Oregon, United States, 97213 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Washington Northwest Medical Specialties Tacoma, Washington, United States, 98045 Canada, Ontario London Health Sciences Centre London, Ontario, Canada, N6A 5W9 Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5T 2M9 Canada, Quebec Hospital de la Cite-de-la-Sante Laval, Quebec, Canada, H7M 3L9 Jewish General Hospital Montreal, Quebec, Canada, H3T 1E2 Less <<
NCT02725541 Breast Cancer Phase 2 Withdrawn(loss of funding supp... More >>ort) Less << May 2019 United States, Texas ... More >> Houston Methodist Hospital Houston, Texas, United States, 77030 Less <<
NCT01702571 Breast Cancer Phase 3 Active, not recruiting September 30, 2019 -
NCT02839681 Lung Neoplasms Phase 2 Terminated - United States, Maryland ... More >> National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 Less <<
NCT03203616 Metastatic HER2-positive Breas... More >>t Cancer With Brain Metastasis Less << Phase 2 Withdrawn(As most HER2+ patien... More >>t develop brain mets while on/after having received TDM1, it has proven to be an insurmountable challenge to recruit patients) Less << - -
NCT03429101 Breast Cancer Phase 1 Recruiting February 2021 United States, California ... More >> Pacific Cancer Medical Center, Inc. Recruiting Anaheim, California, United States, 92801 Contact: Elizabeth Brown    714-999-1465    Elizabethg@pacificcancer.com Less <<
NCT03530696 HER2-positive Breast Cancer ... More >> Breast Cancer Breast Cancer Stage Recurrent Breast Cancer Metastatic Breast Cancer HER2 Positive Breast Carcinoma Less << Phase 2 Not yet recruiting August 1, 2022 -
NCT02996825 Estrogen Receptor Negative ... More >> HER2/Neu Negative Progesterone Receptor Negative Recurrent Breast Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Recurrent Uterine Corpus Carcinoma Triple-Negative Breast Carcinoma Folate Receptor Alpha Positive Less << Phase 1 Recruiting March 2019 United States, California ... More >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Mihaela C. Cristea, MD    800-826-4673    mcristea@coh.org    Principal Investigator: Mihaela C. Cristea, MD          City of Hope Rancho Cucamonga Recruiting Rancho Cucamonga, California, United States, 91730 Contact: Valerie Estala    626-256-4673 ext 81699    vestala@coh.org    Principal Investigator: Behnam Ebrahimi, MD Less <<
NCT03126630 Mesothelin Positive ... More >> Pleural Malignant Mesothelioma Less << Phase 1 Phase 2 Recruiting February 2, 2020 United States, Arizona ... More >> Mayo Clinic Hospital Recruiting Phoenix, Arizona, United States, 85054 Contact: Site Public Contact    855-776-0015       Principal Investigator: Aaron S. Mansfield          Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Site Public Contact    855-776-0015       Principal Investigator: Aaron S. Mansfield          United States, California City of Hope Comprehensive Cancer Center Recruiting Duarte, California, United States, 91010 Contact: Site Public Contact    800-826-4673    becomingapatient@coh.org    Principal Investigator: Marianna Koczywas          United States, Florida Mayo Clinic in Florida Recruiting Jacksonville, Florida, United States, 32224-9980 Contact: Site Public Contact    855-776-0015       Principal Investigator: Aaron S. Mansfield          United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact    888-275-3853       Principal Investigator: James L. Abbruzzese Less <<
NCT02999672 Bladder Cancer ... More >> Pancreas Cancer Cholangiocellular Carcinoma Less << Phase 2 Completed - Italy ... More >> IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica Meldola, Emilia-Romagna, Italy, 47014 Irccs Ospedale San Raffaele;Oncologia Medica Milano, Lombardia, Italy, 20132 Irccs Istituto Europeo Di Oncologia (IEO); Cure Mediche Milano, Lombardia, Italy, 20141 IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima Padova, Veneto, Italy, 35128 A.O.U.I. VERONA-OSPEDALE POLICLINICO G.B. ROSSI BORGO ROMA;ONCOLOGIA MEDICA-d.U. Verona, Veneto, Italy, 37134 Netherlands Antoni van Leeuwenhoek Ziekenhuis Amsterdam, Netherlands, 1066 CX VU Medisch Centrum Amsterdam, Netherlands, 1081 HV UMCG NL -groningen, Netherlands, 9700 RB Erasmus MC - Centrum NL -rotterdam, Netherlands, 3000 CA Slovakia Narodny onkologicky ustav Bratislava, Slovakia, 833 10 Spain Complejo Hospitalario de Navarra Pamplona, Navarra, Spain, 31008 Hospital Univ Vall d'Hebron; Servicio de Oncologia Barcelona, Spain, 08035 Hospital Duran i Reynals; Oncologia Barcelona, Spain, 08907 Hospital Ramon y Cajal; Servicio de Oncologia Madrid, Spain, 28034 Hospital Universitario 12 de Octubre; Servicio de Oncologia Madrid, Spain, 28041 Hospital Regional Universitario Carlos Haya; Servicio de Oncologia Malaga, Spain, 29010 Less <<
NCT00934856 Breast Cancer Phase 1 Phase 2 Completed - United States, North Carolina ... More >> Charlotte, North Carolina, United States, 28203 United States, Texas Houston, Texas, United States, 77005 France Dijon, France, 21079 Saint Herblain, France, 44805 Spain Barcelona, Spain, 08003 Madrid, Spain, 28007 Madrid, Spain, 28040 United Kingdom Dundee, United Kingdom, DD1 9SY Less <<
NCT00934856 - Completed - -
NCT02675829 Solid Tumor Cancers ... More >> Lung Cancer Bladder Cancer Urinary Tract Cancers Less << Phase 2 Recruiting February 2019 United States, New York ... More >> Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Bob Li, MD    646-888-4201       Contact: Gopakumar Iyer, MD    646-422-4362       Principal Investigator: Bob Li, MD Less <<
NCT01439152 Oncology Phase 1 Active, not recruiting May 31, 2019 United States, Connecticut ... More >> New Haven, Connecticut, United States, 06520-8063 United States, Illinois Chicago, Illinois, United States, 60637 United States, Maryland Bethesda, Maryland, United States, 20892 United States, Michigan Detroit, Michigan, United States, 48201 United States, Oklahoma Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Nashville, Tennessee, United States, 37203 United States, Texas Dallas, Texas, United States, 75251 Houston, Texas, United States, 77030 Less <<
NCT02420873 Leukemia Phase 2 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02452554 Pleuropulmonary Blastoma ... More >> Recurrent Malignant Peripheral Nerve Sheath Tumor Recurrent Neuroblastoma Recurrent Rhabdomyosarcoma Recurrent Synovial Sarcoma Wilms Tumor Less << Phase 2 Active, not recruiting - -
NCT01702558 Solid Tumors Phase 2 Completed - -
NCT02420873 - Completed - -
NCT03023722 Pancreatic Cancer Phase 2 Recruiting December 2019 United States, Connecticut ... More >> Yale Cancer Center Recruiting New Haven, Connecticut, United States, 06510 Contact: Stacey S. Stein, MD       stacey.stein@yale.edu    Contact: Kamil Sadowski       kamil.sadowski@yale.edu    United States, New Jersey Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08901-2163 Contact: Howard Hochster, MD          Principal Investigator: Howard Hochster, MD          United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Principal Investigator: Dana Cardin, MD Less <<
NCT03106077 Malignant Neoplasm of Breast Phase 2 Recruiting June 2020 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact       smoulder@mdanderson.org Less <<
NCT03552471 BRCA1 Gene Mutation ... More >> BRCA2 Gene Mutation Folate Receptor Alpha Positive Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Recurrent Uterine Corpus Carcinoma Recurrent Uterine Serous Carcinoma Recurrent Uterine Carcinosarcoma Platinum Resistant Ovarian Cancer Less << Phase 1 Recruiting August 29, 2021 United States, Ohio ... More >> Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Floor Backes, MD    614-293-3873       Principal Investigator: Floor Backes Less <<
NCT02696642 Neoplasms Phase 1 Active, not recruiting June 28, 2019 France ... More >> Caen, France, 14073 Dijon, France, 21000 Lille Cedex, France, 59020 Lyon Cedex, France, 69008 Marseille, France, 13915 Saint Herblain, France, 44805 Toulouse Cedex 9, France, 31059 Moldova, Republic of Chisinau, Moldova, Republic of, 2025 Less <<
NCT02289833 Non-Small Cell Lung Cancer Phase 2 Completed - United States, Florida ... More >> Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy) Jacksonville, Florida, United States, 32256 United States, Illinois Rush University Medical Center Chicago, Illinois, United States, 60612 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, North Carolina University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27514 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 Germany HELIOS Klinikum Emil von Behring Klinik f.Pneumologie Onkologie u.Infektiologie Berlin, Germany, 14165 Kaiserswerther Diakonie Florence Nightingale-Krankenh. Tagesklinik f.Onkologie Düsseldorf, Germany, 40489 Asklepios-Fachkliniken Muenchen-Gauting; Onkologie Gauting, Germany, 82131 Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II Halle, Germany, 06120 Fachklinik für Lungenerkrankungen Immenhausen, Germany, 34376 Italy Azienda Ospedaliera Univ Parma; Dept Oncologia Medica Parma, Emilia-Romagna, Italy, 43100 Istituto Europeo Di Oncologia Milano, Lombardia, Italy, 20141 Korea, Republic of Seoul National University Hospital Seoul, Korea, Republic of, 03080 Asan Medical Center Seoul, Korea, Republic of, 05505 Poland Medical University of Gdansk Gdansk, Poland, 80-211 Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii Otwock, Poland, 05-400 Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii Warszawa, Poland, 02-781 Spain Hospital Univ Vall d'Hebron; Servicio de Oncologia Barcelona, Spain, 08035 Hospital Ramon y Cajal; Servicio de Oncologia Madrid, Spain, 28034 Hospital Universitario La Paz; Servicio de Oncologia Madrid, Spain, 28046 Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia Zaragoza, Spain, 50009 Switzerland CHUV; Departement d'Oncologie Lausanne, Switzerland, 1011 UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie Zürich, Switzerland, 8091 Less <<
NCT02254031 Breast Neoplasms Phase 1 Terminated - -
NCT02254018 Head and Neck Neoplasms Phase 1 Completed - -
NCT02254044 Carcinoma, Squamous Cell Phase 1 Terminated - -
NCT02485119 Neoplasms Phase 1 Completed - Japan ... More >> National Cancer Center Hospital East Kashiwa, Chiba, Japan, 277-8577 National Cancer Center Hospital Tyuo, Japan, 104-0045 Less <<
NCT02289833 - Completed - -
NCT01565200 HER-2 Positive Breast Cancer Phase 2 Active, not recruiting December 2019 Belgium ... More >> Universitair Ziekenhuis Antwerpen (UZA) Antwerpen, Edegem, Belgium, 2650 Institut Jules Bordet Brussels, Belgium, 1000 Netherlands Vrije Universiteit Amsterdam (VUMC) Amsterdam, Netherlands, 1081HV University Medical Center Groningen (UMCG) Groningen, Netherlands, 9700RB Radboud University Medical Centre Nijmegen (UMCN) Nijmegen, Netherlands, 6525 GA Less <<
NCT03153163 Breast Neoplasms Phase 1 Completed - China ... More >> Fudan University Shanghai Cancer Center; Medical Oncology Shanghai, China, 200032 Less <<
NCT02254005 Breast Neoplasms Phase 1 Completed - -
NCT01470456 Diffuse Large B-Cell Lymphoma Phase 2 Completed - Austria ... More >> Investigational Site Number 040002 Graz, Austria, 8036 France Investigational Site Number 250004 Creteil Cedex, France, 94010 Investigational Site Number 250009 Dijon, France, 21000 Investigational Site Number 250006 Lille Cedex, France, 59037 Investigational Site Number 250011 Marseille Cedex 9, France, 13273 Investigational Site Number 250010 Montpellier, France, 34295 Investigational Site Number 250008 Nantes Cedex 01, France, 44093 Investigational Site Number 250007 Paris Cedex 10, France, 75475 Investigational Site Number 250001 Pierre Benite Cedex, France, 69495 Investigational Site Number 250005 Rennes, France, 35033 Investigational Site Number 250003 Rouen Cedex, France, 76038 Investigational Site Number 250002 Villejuif Cedex, France, 94805 Norway Investigational Site Number 578001 Oslo, Norway, 0440 Less <<
NCT02221505 cKIT-positive Solid Tumors ... More >> AML Less << Phase 1 Terminated - Australia, Victoria ... More >> Novartis Investigative Site Parkville, Victoria, Australia, 3050 Belgium Novartis Investigative Site Leuven, Belgium, 3000 Netherlands Novartis Investigative Site Leiden, Netherlands, 2300 RC Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08035 Less <<
NCT01440179 Acute Lymphocytic Leukaemia Phase 2 Terminated(The study is stoppe... More >>d due to very modest activity compared to competitors) Less << - United States, Colorado ... More >> Investigational Site Number 840006 Denver, Colorado, United States, 80218 United States, Tennessee Investigational Site Number 840003 Nashville, Tennessee, United States, 37203 United States, Texas Investigational Site Number 840001 Houston, Texas, United States, 77030 Investigational Site Number 840002 San Antonio, Texas, United States, 78229 United States, Wisconsin Investigational Site Number 840004 Milwaukee, Wisconsin, United States, 53226 France Investigational Site Number 250006 Amiens, France, 80054 Investigational Site Number 250001 Paris Cedex 10, France, 75475 Investigational Site Number 250002 Pessac, France, 33600 Investigational Site Number 250008 Pierre Benite, France, 69310 Investigational Site Number 250004 Rennes, France, 35033 Investigational Site Number 250005 Strasbourg, France, 67200 Less <<
NCT01472887 Diffuse Large B-cell Lymphoma Phase 2 Completed - United States, Colorado ... More >> Investigational Site Number 840001 Denver, Colorado, United States, 80262 United States, Georgia Investigational Site Number 840003 Augusta, Georgia, United States, 30912 United States, Idaho Investigational Site Number 840005 Boise, Idaho, United States, 83712 Belgium Investigational Site Number 056002 Gent, Belgium, 9000 Investigational Site Number 056001 Leuven, Belgium, 3000 Czechia Investigational Site Number 203002 Brno, Czechia, 62500 Investigational Site Number 203003 Praha 10, Czechia, 10034 Investigational Site Number 203001 Praha 2, Czechia, 12808 Israel Investigational Site Number 376003 Jerusalem, Israel, 91120 Investigational Site Number 376002 Tel Hashomer, Israel, 52621 Italy Investigational Site Number 380002 Bergamo, Italy, 24127 Investigational Site Number 380004 Bologna, Italy, 40138 Investigational Site Number 380008 Mestre, Italy, 30174 Investigational Site Number 380001 Milano, Italy, 20133 Investigational Site Number 380007 Modena, Italy, 41100 Investigational Site Number 380003 Palermo, Italy, 90145 Investigational Site Number 380006 Pavia, Italy, 27100 Poland Investigational Site Number 616003 Brzozow, Poland, 36-200 Investigational Site Number 616002 Kielce, Poland, 25-734 Investigational Site Number 616001 Warszawa, Poland, 04-141 Spain Investigational Site Number 724002 Barcelona, Spain, 08003 Investigational Site Number 724004 Barcelona, Spain, 08035 Investigational Site Number 724001 Madrid, Spain, 28046 Investigational Site Number 724003 Valencia, Spain, 46010 Turkey Investigational Site Number 792003 Izmir, Turkey, 35040 Investigational Site Number 792001 Izmir, Turkey, 35340 United Kingdom Investigational Site Number 826001 Leicester, United Kingdom Investigational Site Number 826002 Manchester, United Kingdom, M20 4BX Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.44mL

0.29mL

0.14mL

7.22mL

1.44mL

0.72mL

14.45mL

2.89mL

1.44mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories